Selective Serotonin Reuptake Inhibitors (SSRIs), Childhood and Adolescent Depression, and Suicidality Following the FDA's 2004 Black Box Warning: A Systematized Literature Review

TL;DR

This review examines the link between SSRIs and increased suicidality in adolescents with depression after an FDA warning, finding a small risk that highlights the need for close monitoring.

Contribution

The study provides a systematized review of post-2004 evidence on SSRI use and suicidality in adolescents, offering updated insights into treatment risks and benefits.

Findings

Observational studies found a small increase in suicidal risk with SSRI use, especially early in treatment.

Combination therapy with SSRIs and CBT showed better outcomes and lower suicidality rates.

RCTs showed mixed results, with some finding increased suicidality with SSRI monotherapy and others finding no significant association.

Abstract

Major depressive disorder (MDD) in adolescents is a significant public health concern. When left untreated, it can lead to poor academic performance, substance use, and a heightened risk of suicide. The U.S. Food and Drug Administration (FDA) issued a black box warning on selective serotonin reuptake inhibitors (SSRIs) for patients under 18 due to concerns about increased suicidality - a decision that remains debated given SSRIs’ role as first-line treatment for depression and the inherent suicide risk of untreated MDD.

This systematized literature review examined the current evidence on the association between SSRI use and suicidality in adolescents with MDD following the FDA black box warning. Following a comprehensive PubMed search, studies were selected using predefined inclusion and exclusion criteria. Eight studies were selected for further data extraction and synthesis.

Overall, observational studies found a small but measurable increase in suicidal risk with SSRI use, particularly during the early treatment phase, highlighting the need for close monitoring. Two randomized controlled trials (RCTs) reported increased treatment-emergent suicidality with SSRI monotherapy compared to cognitive behavioral therapy (CBT) or combination therapy, while two other RCTs found no significant association. Across studies, combination therapy with SSRIs and CBT tended to yield better outcomes and lower rates of suicidality.

Current evidence reveals that SSRI treatment in childhood and adolescent MDD is associated with a small but measurable increase in suicidality, particularly in early treatment, underscoring the need for close clinical monitoring and concurrent psychotherapy. Clinicians are encouraged to monitor closely for suicidality during early treatment and to carefully weigh the benefits of SSRIs against the risks of untreated depression.

Figures